For decades, paediatric anticoagulation has been guided more by extrapolation than by evidence. Treatments for venous thromboembolism in children have largely mirrored adult practice, despite ...
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...
But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...
BACKGROUND: Direct oral anticoagulants such as apixaban and rivaroxaban, have transformed the management of thromboembolic ...
Apixaban is a generic oral tablet that’s prescribed for certain types of blood clots. It’s available as the brand-name drug Eliquis. The cost of apixaban, with and without insurance, can depend on ...
In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...
A large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease (VHD) found that use of apixaban was associated with a lower rate of ischemic stroke or systemic ...
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a ...
When older adults with atrial fibrillation (AF) are starting on a direct oral anticoagulant (DOAC) for stroke prevention, they may be better off with apixaban than rivaroxaban. In a study of claims ...
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban, having considered evidence on the nature of non-valvular atrial fibrillation and the value ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban, having considered evidence on the nature of venous thromboembolism and the value placed on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results